GTHA News GeneThera Announces Formation of ApiGen with Nutricion Avanzada Internacional S.A. de. CV.
WHEAT RIDGE, Colo.--(BUSINESS WIRE)--In line with its strategic direction to commercialize a live animal test
for Johne’s Disease, GeneThera (OTCBB:GTHA)
announces the formation of a new company in Mexico with Nutrición
Avanzada Internacional S.A. de C.V. of Monterrey, Mexico.
The new company will be named ApiGen Inc. and has been formed to
commercialize a test in Mexico for Johne’s
Disease.
GeneThera and Nutrición Avanzada will be
equal partners in ApiGen and share equally in all profits from the
commercialization of their Johne’s test.
GeneThera will gain access to Nutrición
Avanzada’s customer base as well as gaining a
physical presence in Mexico at Nutrición
Avanzada’s Monterrey facilities.
Commenting on the new company, Dr. Tony Milici, CEO of GeneThera, said, “We
are very happy to have formed this Mexico-based company with our
alliance partner Nutrición Avanzada of
Monterrey, Mexico. This new company will allow us to generate revenues
from the testing of the dairy cattle population in Mexico. We expect to
start testing as early as the first quarter of 2007.”
Sergio I. González, principal of Nutrición
Avanzada of Monterrey, Mexico, said, “We couldn’t
be more thrilled with the formation of this company with GeneThera. We
look forward to generating revenue within ApiGen by being able to offer
this much needed blood based Johne’s test.”
Johne's Disease (pronounced "yo-knees") is a contagious, chronic and
usually fatal infection that affects primarily the small intestine of
ruminants. All ruminants are susceptible to Johne's Disease. Johne's
Disease is caused by Mycobacterium avium subspecies paratuberculosis,
a hardy bacteria related to the agents of leprosy and tuberculosis. The
disease is worldwide in distribution. A national study of US dairies,
Dairy NAHMS 96, found that approximately 22 percent of US dairy farms
have at least 10% of the herd infected with Johne's Disease. The study
determined that infected herds experience an average loss of $40 per cow
in herds with a low Johne’s Disease clinical
cull rate while herds with a high Johne’s
Disease clinical cull rate lost on average of $227. This loss was due to
reduced milk production, early culling, and poor conditioning at culling.
ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology company located in Wheat
Ridge, CO. The Company provides genetic diagnostic solutions for the
veterinary and agricultural industries with future plans to include the
health-care industry. The Company's proprietary diagnostic solution is
based on a genetic expression assay, GEA™, a
protocol designed to function on a highly automated Fluorogenic PCR
platform. This platform enables GeneThera to offer tests that are
presently not available from other technologies. The GEA™
is designed for a host of individual diseases, the current priority
being Mad Cow Disease; Chronic Wasting Disease, a disease affecting elk
and deer in North America; E.Coli 0157:H7; and Johne's Disease; diseases
affecting cattle worldwide.
Stay up to date with MN1 NewsWire “NEWS
YOU CAN TRUST” at www.MN1.com.
"Safe Harbor" Statement: Certain statements in this release are
"forward-looking" statements as defined in the Private Securities
Litigation Reform Act of 1995. Such statements are subject to numerous
risks and uncertainties. Actual results may vary significantly from the
results expressed or implied in such statements. Factors that could
cause actual results to materially differ from forward-looking
statements include, but are not limited to, the Company's ability to
meet the terms and conditions required to obtain its project financing,
risks and delays associated with product development, risk of market
acceptance of new products, risk of technology or product obsolescence,
competitive risks, reliance on development partners and the need for
additional capital.
